Health ❯ Healthcare ❯ Clinical Trials

Drug Development

Combination Therapy Phase 3 Trials Eli Lilly Targeted Therapy Phase III Trials Oncology Alzheimer's Treatments RAS Inhibitors Daraxonrasib Patient Outcomes

3 ARTICLES

10h ago

Study Maps How Leukemia Enters Lungs and Identifies Drug Targets

The June 29 Nature Immunology paper identifies galectin-9 and the IL-33 receptor as drivers of lung inflammation whose blockade halted leukemic entry in experiments.

Stories older than 24h

6 ARTICLES

last wk.

Biogen to Buy RayThera for Up to $1 Billion

5 ARTICLES

2w ago

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

3 ARTICLES

2w ago

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

4 ARTICLES

3w ago

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

11 ARTICLES

3w ago

Abivax Drug Shows Breakthrough Ulcerative Colitis Results as Shares Plunge After Cancer Cases

12 ARTICLES

3w ago

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

4 ARTICLES

4w ago

Experimental ERAP1 Inhibitor Plus Immunotherapy Shrinks Tumours in Early Trial

3 ARTICLES

4w ago

Praxis Drug Vormatrigine Misses Primary Goal in Phase 2/3 POWER1 Trial

35 ARTICLES

4w ago

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

5 ARTICLES

4w ago

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

3 ARTICLES

4w ago

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

3 ARTICLES

4w ago

Mezigdomide Triplet Cuts Risk of Myeloma Progression by 52% in Phase 3 Trial

3 ARTICLES

4w ago

NEJM Paper Shows Zanidatamab Triplet Extends Survival Over Trastuzumab in First‑Line HER2+ Gastroesophageal Cancer

35 ARTICLES

last mo.

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

5 ARTICLES

last mo.

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

7 ARTICLES

last mo.

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

3 ARTICLES

last mo.

Sanofi’s Efdoralprin Alfa Beats Standard Therapy in Phase 2 AATD Trial

4 ARTICLES

last mo.

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

11 ARTICLES

last mo.

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

Drug Development

Study Maps How Leukemia Enters Lungs and Identifies Drug Targets

Biogen to Buy RayThera for Up to $1 Billion

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

Abivax Drug Shows Breakthrough Ulcerative Colitis Results as Shares Plunge After Cancer Cases

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

Experimental ERAP1 Inhibitor Plus Immunotherapy Shrinks Tumours in Early Trial

Praxis Drug Vormatrigine Misses Primary Goal in Phase 2/3 POWER1 Trial

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Never miss stories about

Drug Development

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

Mezigdomide Triplet Cuts Risk of Myeloma Progression by 52% in Phase 3 Trial

NEJM Paper Shows Zanidatamab Triplet Extends Survival Over Trastuzumab in First‑Line HER2+ Gastroesophageal Cancer

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

Sanofi’s Efdoralprin Alfa Beats Standard Therapy in Phase 2 AATD Trial

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

Never miss stories about

Drug Development